An FDA advisory panel narrowly recommended expanding access to compounded, unapproved peptides, endorsing broader use of four products despite objections from scientists and concerns about the evidence base. The discussion centered on whether bulk-drug listing for peptides would create an end-run around the agency’s standard safety and efficacy review. Separate FDA advisory proceedings also advanced decisions on whether additional unapproved peptides should be added to the Section 503A Bulk Drug Substances List, which would materially broaden what compounding pharmacies can produce. The votes are non-binding, but they signal momentum for a regulatory loosening that has drawn criticism from patient-safety advocates. The filings and deliberations are unfolding against a politically charged backdrop and are likely to shape how quickly pharmacists and patients can access little-studied compounds through compounding channels—distinct from pathway drugs supported by clinical trials and manufacturing controls. For biotech stakeholders, the panel’s stance underscores renewed regulatory risk for companies developing evidence-based peptide therapies: a less standardized route to supply could complicate commercial expectations and intensify scrutiny of compounding manufacturing quality.